Roche's Oncology Drug Strategy Emphasizes Comprehensive Diagnostics
This article was originally published in The Gray Sheet
Executives emphasized the role of "comprehensive diagnostics" in its plan to establish a dominant position in immuno-oncology drugs at this years' American Society of Clinical Oncology annual meeting.
You may also be interested in...
FDA approved Roche's Ventana PD-L1 assay to help identify patients more likely to respond to its Tecentriq drug for bladder cancer. It's approved as a helpful tool, rather than required test, with the drug, but the assay is part of a growing class of diagnostics that are likely to play an important supporting role in a promising and high-growth branch of oncology.
"The Gray Sheet" offerings that captured the most Web traffic last month centered on device recall trends, combination products, exclusive interviews with two FDA officials and our new Device Week podcast.
The US companion diagnostics sector is predicted to grow from $1.6 billion to $6.2 billion between 2015 and 2021, a CAGR of 25.3%, outpacing the IVD market growth fivefold. This rapid growth will be driven by the development of new targeted pharmaceutical products and moves by the FDA to quickly approve new treatments and diagnostics together.